Compare Corning Incorporated (GLW) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Pfizer Inc — how do they compare? Corning Incorporated trades at $156.91 (market cap $140.62B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Corning Incorporated and Pfizer Inc are close in size by market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 35 Days and Pfizer Inc for 158 Days on average.
| GLW | PFE | |
|---|---|---|
Market Cap | $140.62B | $159.59B |
Volume | 5,163,560 | 30,937,010 |
Sector | Technology | Health |
52-Week High | $255.79 | $29.02 |
52-Week Low | $78.03 | $23.67 |
Typical Hold Time | 35 Days | 158 Days |
Enterprise Value | $147.50B | $211.09B |
Dividend Yield | 0.69% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $163.21, down 3.41% today, but maintains a bullish technical outlook with strong support at $160. The company recently secured a significant $3 billion fiber supply agreement with AT&T, boosting growth prospects in the AI infrastructure sector. Despite elevated valuation ratios (P/E 75.23), GLW has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $0.878. Operating cash flow improved to $2.7 billion in 2025, supporting the company's dividend payments and strategic investments.
GLW presents a compelling growth story driven by AI infrastructure demand, with analyst consensus favoring Buy ratings (56.75%) and a $171.25 price target offering 5% upside. Key risks include patent litigation concerns and the stock's premium valuation requiring sustained earnings growth. The AT&T partnership positions Corning to capitalize on expanding fiber optic needs, though investors should monitor competitive pressures and execution risks in the rapidly evolving technology sector.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
